Attitudes and practice in the management of metastatic colorectal cancer in Britain

doi:10.1016/S0936-6555(97)80010-6

Clinical Oncology

Volume 9, Issue 4, 1997, Pages 248-251

https://doi.org/10.1016/S0936-6555(97)80010-6 Get rights and content

Abstract

Evidence-based medicine is widely held to be the essential basis of modern therapeutics. The principle of adopting into clinical practice those treatments proved to be of value in randomized trials, or in the systematic review of several trials, is encouraging a welcome proliferation of clinical research and meta-analysis. However, many things affect clinical practice; quantifiable therapeutic benefit is only one of them. Furthermore, in many situations, clear evidence of the best treatment is not available. When discussing ideas for a new trial in advanced colorectal cancer that was launched in 1996, the MRC Colorectal Cancer Working Party carried out a survey of the attitudes and practice of surgeons and oncologists who were treating this condition. This revealed substantial diversity of practice amongst experts in the treatment of this common disease, and prompted us to review the factors that affect clinical practice and to discuss the implications.

References (16)

Allen-MershTG et al.
Quality of life and survival with continuous hepatic artery floxuridine infusion for colorectal liver metastases
Lancet
(1994)
MaynardA
Evidence-based medicine: an incomplete method for informing treatment choices
Lancet
(1997)
Cancer Research Campaign
Factsheets 3.2–3.3 (UK cancer statistics)
(1995)
SeymourMT et al.
A randomized trial assessing the addition of interferon α2a to 5-fluorouracil and leucovorin in advanced colorectal cancer
J Clin Oncol
(1996)
ScheeleJ et al.
Resection of colorectal liver metastases
World J Surg
(1995)
ScheithauerW et al.
Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer
BMJ
(1993)
Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial
J Clin Oncol
(1992)
BerettaG et al.
Fluorouracil + folates as standard treatment for advanced/metastatic gastrointestinal carcinomas [abstract]
Ann Oncol
(1994)

There are more references available in the full text version of this article.

Cited by (54)

Pulmonary metastasectomy for colorectal cancer: Long-term survival and prognostic factors
2013, International Journal of Surgery
Citation Excerpt :
More than half of all patients who undergo resection for colorectal carcinoma are expected to have recurrence of their disease, and the most frequent sites of distant recurrences are the liver and the lungs.1,2 Patients with untreated metastatic disease have a median survival of less than one-year and a five-year survival of less than 5%.3 Despite the development of novel chemotherapy and biological agents, surgery is still an important option for patients with pulmonary metastases.
Despite the development of novel chemotherapy and biological agents, surgery is still an important option for patients with pulmonary metastases. Predictors of survival usually include disease-free interval, histology of the primary tumor, number of metastases and complete resection. The aim of this study was to report the outcomes of patients with pulmonary metastases from colorectal carcinoma submitted to surgical resection, and to identify prognostic factors that significantly affect overall survival.
We retrospectively analyzed 120 patients with previously treated colorectal carcinoma that had developed pulmonary metastases, admitted between 1990 and 2006. Overall survival was estimated using Kaplan–Meier analysis. The log-rank and Breslow tests were used to compare survival differences for each variable. Multivariate analyses to determine the independent prognostic factors for overall survival were performed using the Cox proportional hazard model as identified by the univariate analyses.
The median follow-up was 20.3 months (range: 3.27–134.2 months). The patients included in this study underwent a total of 165 thoracotomies (mean of 1.37 thoracotomies/patient). The median overall survival for all patients was 34.73 months, with an estimated 5-year survival rate of 24.39%. Multivariate analyses identified unilateral lesions, neoadjuvant chemotherapy at lung resection and complete resection as independent prognostic factors for overall survival.
These results indicate that prognostic factors identified in studies on pulmonary metastasectomy for all primary tumors should be interpreted carefully for patients with possibility of pulmonary metastasectomy from colorectal carcinoma.
Pulmonary metastases from colorectal cancer: Imaging findings and growth rates at follow-up CT
2012, Clinical Imaging
Citation Excerpt :
Pulmonary metastases develop in 5%–15% of all colorectal cancer (CRC) patients, and performing resection of the pulmonary metastases from CRC has yielded 5-year survival rates ranging from 20% up to 60% in several large series, while patients with untreated metastatic disease have 5-year survival rates of less than 5% [1,2].
The objective of the study was to evaluate the computed tomographic (CT) features and growth rates of pulmonary metastases from colorectal cancer (CRC) on serial CT scans. The study included 17 patients (28 pulmonary metastases) who underwent metastasectomy from CRC. The characteristic CT features include well-defined round or oval nodules in the peripheral or subpleural/fissural lung with frequent feeding vessel sign. The mean tumor volume doubling time was calculated as 160 days. With these growth rates, short-term follow-up (i.e., 5–6 months) would be helpful.
Early intrapulmonary recurrence after pulmonary metastasectomy related to colorectal cancer
2010, Annals of Thoracic Surgery
Early intrapulmonary recurrence is a major problem after pulmonary metastasectomy related to colorectal cancer. However, the risk factors for early intrapulmonary recurrence are not clear.
Between August 2001 and December 2007, 125 patients underwent pulmonary metastasectomy after colorectal cancer. The prognostic factors for overall survival were evaluated, including early (within 6 months) intrapulmonary recurrence. The factors related to early intrapulmonary recurrence were also analyzed.
Thirteen patients (10.4%) had early intrapulmonary recurrence. The median follow-up was 46 months (range, 21 to 99). Early intrapulmonary recurrence (hazard ratio 2.716; 95% confidence interval: 1.027 to 7.182; p = 0.044), extrapulmonary metastasectomy, metastatic hilar or mediastinal lymph nodes, and high prethoracotomy carcinoembryonic antigen levels were independent prognostic factors on multivariate analysis. Extrapulmonary metastasectomy (odds ratio 4.840; 95% confidence interval: 1.314 to 17.821; p = 0.018) and bilateral pulmonary metastasis (odds ratio 6.228; 95% confidence interval: 1.689 to 22.960; p = 0.006) were independent risk factors for early intrapulmonary recurrence.
Early intrapulmonary recurrence after pulmonary metastasectomy related to colorectal cancer is a prognostic factor for poor overall survival. Extrapulmonary metastasectomy and bilateral pulmonary metastasis are risk factors for early intrapulmonary recurrence. Pulmonary metastasectomy in patients with these risk factors should be considered carefully.
Pulmonary Resection for Metastases of Colorectal Adenocarcinoma
2010, Annals of Thoracic Surgery
Surgery is a safe and effective treatment for patients with lung metastases from colorectal carcinoma. Combining chemotherapy and surgery seems to prolong survival time after metastasectomy. Our purpose was to review the effectiveness of surgery with time and evolving managements.
The records of 127 patients were retrospectively analyzed. The characteristics of primary cancer, lung metastases, resections, and associated therapy were studied according to their incidence on survival.
There were 74 male and 53 female patients (mean age, 65 years); 223 operations were performed and 314 metastases were resected. Completeness of surgery (n = 117) was the main factor for prolonged survival (5- and 10-year survival, 41% and 27%, versus 0%). There was no factor of significantly better prognosis, but a tendency to higher survival rates was observed in cases of single metastasis, in patients undergoing several lung operations, and in patients in whom liver metastases were previously removed. Three of 7 patients with mediastinal lymph node involvement survived more than 5 years; 58 patients were operated on before January 2000, and 59 between January 2000 and December 2007. Five-year survival rates were 35.1% versus 63.5%, respectively (p = 0.0096), probably related to better selection with modern workup, more frequent use of chemotherapy, and repeated pulmonary resections.
Different treatment protocols were reported in the literature and in our series with time, resulting in better survival rates and a more aggressive surgical tendency. The beneficial role of such combined therapy justifies further research, including prospective trials.
Comparison of treatment received versus long-standing guidelines for stage III colon and stage II/III rectal cancer patients diagnosed in Alberta, Saskatchewan, and Manitoba in 2004
2009, Clinical Colorectal Cancer
Guideline-recommended treatment for stage II/III colorectal cancer includes postsurgical chemotherapy and/or radiation as standard of care. This study measures adherence to guidelines across 3 Canadian provinces and evaluates the relationship of patient characteristics with receiving standard care.
All surgically treated patients diagnosed in 2004 with stage III colon or stage II/III rectal cancer and residing in Alberta, Saskatchewan, or Manitoba were identified from provincial cancer registries. Sex, age at diagnosis, and area of residence were also obtained from the cancer registry. The primary outcome of interest was receipt of standard care: surgery followed by chemotherapy or radiation therapy (adjuvant therapy). χ² tests and binary regression with log link assessed the relationship of patient demographic characteristics (age, sex, residence, cancer disease stage) with receipt of standard care.
About half of the patients received adjuvant therapy. Patients with stage III rectal cancer were more likely to receive adjuvant treatment than stage II patients in Alberta and Saskatchewan. There was a large decrease in the percentage of patients who received adjuvant treatment with increasing age in all the provinces (P < .001), ranging from about 80% of those aged < 65 years to about 20% of those aged ≥ 75 years for colon cancer patients and from about 70% to 30%, respectively, for rectal cancer patients. The decrease of adjuvant treatment with increasing age was most marked in Alberta.
The percentage of patients receiving guideline-recommended treatment is low. Reasons for lack of adherence to guidelines need to be addressed.
Perimammary uniportal vats fissureless right anterior segmentectomy for lung metastasectomy: a case report
2023, Journal of Visualized Surgery

View all citing articles on Scopus

View full text

Original articleAttitudes and practice in the management of metastatic colorectal cancer in Britain

Abstract

Lancet

Lancet

Factsheets 3.2–3.3 (UK cancer statistics)

A randomized trial assessing the addition of interferon α2a to 5-fluorouracil and leucovorin in advanced colorectal cancer

J Clin Oncol

Resection of colorectal liver metastases

World J Surg

Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer

BMJ

Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial

J Clin Oncol

Fluorouracil + folates as standard treatment for advanced/metastatic gastrointestinal carcinomas [abstract]

Ann Oncol

Original article
Attitudes and practice in the management of metastatic colorectal cancer in Britain